IMMUTEP LIMITED - AMER

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

03 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

24 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

18 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

16 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

20 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

14 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Participate in Upcoming Investor Conferences

07 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q4 FY24

31 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

22 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

17 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

11 7 2024 18:40:40 提供 Nasdaq GlobeNewswire

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

03 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

25 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep successfully completes institutional placement and institutional component of entitlement offer

05 6 2024 06:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

02 6 2024 20:38:39 提供 Nasdaq GlobeNewswire

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

15 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

02 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q3 FY24

29 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

24 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

18 4 2024 08:00:00 提供 Nasdaq GlobeNewswire